<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathophysiology of sickle cell disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathophysiology of sickle cell disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathophysiology of sickle cell disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin H Steinberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael R DeBaun, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sickle hemoglobin (Hb S, alpha2:beta
         <sup>
          S
         </sup>
         2) is a result of a specific point mutation in the gene
         <em>
          HBB
         </em>
         , which encodes hemoglobin beta chains. It substitutes valine for the normal glutamic acid at the seventh amino acid (
         <em>
          HBB
         </em>
         p.glu7val). (See
         <a class="local">
          'Sickle hemoglobin'
         </a>
         below.)
        </p>
        <p>
         Homozygosity for Hb S or compound heterozygosity for Hb S and one of certain other
         <em>
          HBB
         </em>
         variants (including beta thalassemia) causes the phenotype of sickle cell disease (SCD), characterized by vaso-occlusive pain, organ damage, hemolytic anemia, countless disease complications, and shortened survival.
        </p>
        <p>
         This topic discusses the pathophysiology of SCD, including the mechanisms of Hb S polymerization, vaso-occlusion, and hemolysis.
        </p>
        <p>
         Separate topics discuss the clinical consequences of these changes in different organ systems:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General overview
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/110699.html" rel="external">
          "Evaluation of acute pain in sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">
          "Sickle cell disease effects on the kidney"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenic infarction
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Focal splenic lesions'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional asplenia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">
          "Evaluation and management of fever in children and adults with sickle cell disease", section on 'Risk of life-threatening infection'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary complications
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/16353.html" rel="external">
          "Acute chest syndrome (ACS) in sickle cell disease (adults and children)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94999.html" rel="external">
          "Pulmonary hypertension associated with sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stroke
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">
          "Prevention of stroke (initial or recurrent) in sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5926.html" rel="external">
          "Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Priapism
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7143.html" rel="external">
          "Priapism and erectile dysfunction in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1023521420">
         <span class="h1">
          GENETICS
         </span>
        </p>
        <p class="headingAnchor" id="H860010855">
         <span class="h2">
          Sickle hemoglobin
         </span>
         <span class="headingEndMark">
          —
         </span>
         SCD is a monogenic (single gene) disorder due to a specific variant in the beta globin gene,
         <em>
          HBB
         </em>
         , which encodes the beta globin chain of hemoglobin (Hb).
         <em>
          HBB
         </em>
         is located on chromosome 11 (11p 15.4) in the beta globin gene cluster  (
         <a class="graphic graphic_figure graphicRef65642" href="/z/d/graphic/65642.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">
          "Structure and function of normal hemoglobins", section on 'Hemoglobin structure'
         </a>
         .)
        </p>
        <p>
         The sickle cell variant that produces Hb S is a single point mutation that creates an amino acid substitution (valine instead of the normal glutamic acid) at amino acid 7, referred to as p.glu7val  (
         <a class="graphic graphic_figure graphicRef131447" href="/z/d/graphic/131447.html" rel="external">
          figure 2
         </a>
         ). The position of the variant was previously referred to as p.glu6val; this was changed to p.glu7val in the revised convention for amino acid numbering that includes the cleaved initial methionine residue as residue number 1. The p.glu7val mutation is the only point mutation that produces Hb S.
        </p>
        <p>
         Phylogenetic analysis using data from various genome databases determined that Hb S arose over 7000 years ago [
         <a href="#rid1">
          1
         </a>
         ]. The investigation suggested a single origin of the mutation in West or Central Africa, perhaps in the Green Sahara, which was wet and rainy at the time, or in the equatorial rainforest. Malaria was endemic in both areas during the Holocene period. The nearly exclusive presence of the original haplotype in certain regions of Africa suggests a single origin. This likely preceded a population split, possibly in the area of Cameroon, which led to the Bantu expansions approximately 2400 years later (approximately 5000 years ago).
        </p>
        <p>
         SCD is an autosomal recessive trait. For the disease to manifest, there must be homozygosity for Hb S or compound heterozygosity for Hb S and beta thalassemia or a different
         <em>
          HBB
         </em>
         variant that interacts with Hb S. (See
         <a class="local">
          'Compound heterozygous syndromes'
         </a>
         below.)
        </p>
        <p>
         Heterozygosity for Hb S (without a pathogenic variant at the other
         <em>
          HBB
         </em>
         allele) causes sickle cell trait, a usually benign carrier state with approximately 40 percent Hb S, without vaso-occlusion or hemolysis. Carriers have a normal life expectancy and slightly increased risk for thromboembolic disease and impaired kidney function. (See
         <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">
          "Sickle cell trait"
         </a>
         .)
        </p>
        <p>
         Rare variants exist in which two mutations are present on the same
         <em>
          HBB
         </em>
         allele, one of them coding for Hb S and the other for a distinct mutation at another location in the same gene.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first described was a variant called Hb C-Harlem, which had the p.glu7val mutation plus p.asp74asn; together this pair of mutations caused the hemoglobin to comigrate with Hb C on gel electrophoresis. (See
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb C-Harlem'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 15 other variants have been described with Hb S plus another mutation in the same
         <em>
          HBB
         </em>
         allele [
         <a href="#rid2">
          2
         </a>
         ]. Their phenotypes vary in the heterozygous state or as compound heterozygotes with Hb S. Hb S-Antilles (p.glu7val plus p.val24ile) can cause SCD in heterozygotes because this variant produces a Hb that polymerizes more readily than Hb S [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3581694427">
         <span class="h2">
          Compound heterozygous syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compound heterozygous SCD syndromes include coinheritance of Hb S with another
         <em>
          HBB
         </em>
         variant that interacts with Hb S or with beta thalassemia. These compound heterozygous syndromes generally are associated with a Hb S percentage of ≥50 percent. Common examples of the second mutation include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A beta thalassemia mutation (beta
         <sup>
          0
         </sup>
         or beta
         <sup>
          +
         </sup>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb C
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb D Los Angeles (Punjab)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb E
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb O-Arab
        </p>
        <p>
        </p>
        <p>
         These and other less common genotypes that also can cause SCD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7115.html" rel="external">
          "Overview of compound sickle cell syndromes"
         </a>
         .)
        </p>
        <p>
         Most other
         <em>
          HBB
         </em>
         variants that have been described in compound heterozygosity with Hb S do not interact with the Hb S mutation, either directly by increasing polymerization or indirectly by enhancing cell density, akin the effects of Hb C. The variants that do not produce the SCD phenotype are generally associated with the largely benign phenotype of sickle cell trait.
        </p>
        <p>
         The phenotype of compound heterozygosity with beta thalassemia depends on the specific beta thalassemia variant. (See
         <a class="medical medical_review" href="/z/d/html/7131.html" rel="external">
          "Molecular genetics of the thalassemia syndromes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta thalassemia variants that permit some normal Hb A expression (referred to as beta
         <sup>
          +
         </sup>
         ) in combination with Hb S have a higher Hb S level than sickle cell trait. Depending on the Hb A level (which can range from &lt;5 percent to &gt;45 percent), vaso-occlusion and hemolysis can be severe or mild.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta thalassemia variants that produce no hemoglobin (referred to as beta
         <sup>
          0
         </sup>
         ) in combination with Hb S have a phenotype much like that of homozygosity for Hb S. They are characterized by an absence of normal Hb A, with only Hbs S and F, and increased levels of Hb A2.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2150856996">
         <span class="h2">
          Modifier genes (Hb F, alpha thalassemia, PKLR)
         </span>
         <span class="headingEndMark">
          —
         </span>
         SCD is clinically heterogeneous. Individuals with identical Hb genotypes can have different frequencies of vaso-occlusive pain, variable rates of hemolysis, and different spectra of chronic complications. These differences are due partly to the modulating effects of modifier genes. The two most important genetic modifiers of the phenotype of SCD are levels of fetal hemoglobin (Hb F) and the presence of coincident alpha thalassemia. Variants in
         <em>
          PKLR
         </em>
         , the gene for pyruvate kinase (PK) deficiency, are also under investigation as disease modifiers. (See
         <a class="medical medical_review" href="/z/d/html/7129.html" rel="external">
          "Pyruvate kinase deficiency"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hb F
         </strong>
         – Fetal hemoglobin (Hb F; alpha2:gamma2) and Hb A2
         <sub>
         </sub>
         (alpha2:delta2)
         <strong>
          directly
         </strong>
         inhibit Hb S polymerization because these hemoglobins and their hybrid tetramers (alpha2:gamma,beta
         <sup>
          S
         </sup>
         ; alpha2:delta,beta
         <sup>
          S
         </sup>
         ) cannot be incorporated into the Hb S polymer [
         <a href="#rid3">
          3
         </a>
         ]. Both the gamma chain of Hb F and the delta chain of Hb A2 have a glutamine residue at position 87 that accounts for a major portion of their anti-polymerization effects [
         <a href="#rid4">
          4
         </a>
         ]. Gene therapy constructs that take advantage of this property are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Anti-sickling beta globin gene'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha thalassemia
         </strong>
         – Alpha thalassemia, discussed below,
         <strong>
          indirectly
         </strong>
         inhibits polymerization by decreasing alpha globin chain synthesis, thereby reducing mean corpuscular hemoglobin concentration (MCHC). (See
         <a class="local">
          'Effects of concomitant alpha thalassemia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PKLR
         </strong>
         –
         <em>
          PKLR
         </em>
         variants are common in people of African descent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One study found a group of
         <em>
          PKLR
         </em>
         variants was associated with increased risk of hospitalization for acute sickle cell pain, although no information was provided about 2,3 BPG levels or hemoglobin-oxygen affinity, the most likely effectors of PK deficiency on the phenotype of SCD [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an informative case report, a genetic variant of
         <em>
          PKLR
         </em>
         was associated with acute painful episodes in sickle cell trait, which is usually an asymptomatic carrier state [
         <a href="#rid6">
          6
         </a>
         ]. In this case, severe PK deficiency was present and was associated with 2,3 BPG levels nearly twice normal and P50 of 41.5 mm Hg (versus 25 mm Hg in controls), hemoglobin 8.5 g/dL, and frequent episodes of acute sickle cell pain. The presence of variant
         <em>
          PKLR
         </em>
         alleles in SCD noted above was associated with heterozygosity for intronic variants of unknown pathophysiologic significance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PK activators that decrease 2,3 BPG, thereby increasing hemoglobin-oxygen affinity and decreasing P50, are being studied as treatments for SCD. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Pyruvate kinase activation (mitapivat, etavopivat)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – It is likely that disease modifying genes and environmental factors that affect other aspects of Hb polymerization and the vaso-occlusive and hemolytic process, including vascular endothelial cells or mediators of inflammation, are also important contributors to disease heterogeneity. Many have been described but few have been independently verified [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">
          "Basic genetics concepts: DNA regulation and gene expression", section on 'Genetic variation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1758323855">
         <span class="h1">
          HB S POLYMERIZATION AND FIBER FORMATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hb S polymerization is the primary, indispensable, initiating pathophysiologic event in SCD from which all of the other pathophysiologic changes arise [
         <a href="#rid8">
          8
         </a>
         ]. Therapies that target primarily Hb S polymerization reduce both vaso-occlusion and hemolytic anemia.
        </p>
        <p>
         Two approved drugs and gene therapy approaches have a primary effect on Hb S polymerization:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         induces increased levels of Hb F that interrupts the polymerization process. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">
          Voxelotor
         </a>
         prevents polymerization by keeping the Hb S molecule in the oxy configuration, which cannot polymerize. (See
         <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">
          "Disease-modifying therapies to prevent pain and other complications of sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some gene therapy approaches can greatly increase Hb F or add a Hb F-like Hb A molecule, and these appear to abate acute vaso-occlusive events and correct hemolytic anemia [
         <a href="#rid9">
          9-11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Therapies with curative intent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3693932291">
         <span class="h2">
          Deoxygenation-sickling cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         Normal Hbs are soluble in the cytoplasm of the red blood cell (RBC). Hb S forms insoluble polymers when deoxygenated.
        </p>
        <p>
         The primary modulator of oxygen affinity in the RBC is 2,3 bisphosphoglycerate (2,3-BPG, also called 2,3-DPG). Increased 2,3-BPG favors Hb S polymerization in three ways [
         <a href="#rid12">
          12,13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It lowers oxygen affinity, increasing deoxy Hb S.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It reduces intracellular pH, increasing deoxy Hb S.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It alters the conformation of deoxy Hb S.
        </p>
        <p>
        </p>
        <p>
         Reducing 2,3-BPG by activators of RBC pyruvate kinase is being studied as a method of decreasing P50 and reducing Hb S polymerization. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Reducing Hb S polymerization'
         </a>
         .)
        </p>
        <p>
         The structure of Hb S when in solution (not polymerized) is nearly identical with that of Hb A, and the two Hbs have identical oxygen binding curves in dilute solution [
         <a href="#rid14">
          14
         </a>
         ]. However, at concentrations above the solubility of deoxy Hb S that cause polymerization, the Hb-oxygen binding curve is progressively right shifted  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid15">
          15-17
         </a>
         ]. Since Hb S polymerizes only when it is in the tense (T) quaternary conformation, the polymer binds oxygen non-cooperatively and with low affinity [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H497850288">
         <span class="h2">
          Hb polymerization
         </span>
         <span class="headingEndMark">
          —
         </span>
         The polymerization of Hb S is a simple phase change from solution to gel. It is an endothermic process facilitated by hydrophobic interactions [
         <a href="#rid19">
          19-21
         </a>
         ]. The mechanism of polymer formation involves the self-association of Hb molecules; no accessory proteins are involved. It is entropically driven, resulting from the release of ordered water molecules from the surface of free Hb.
        </p>
        <p>
         The assembly process obeys classic chemical rules of kinetics and thermodynamics, with a polymerization rate that depends on the concentration of Hb S, intracellular oxygen tension, pH, and temperature [
         <a href="#rid22">
          22-24
         </a>
         ]. The glutamic acid at amino acid 7 seems to be especially important in preventing polymerization, via its electrostatic (repulsive) interactions with asparagine at amino acid 74 [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The contact between the valine 7 on the beta2 subunit and the acceptor site on the partner strand is only possible when Hb S is in the T conformation. In the R (relaxed, oxygenated) state, Hb S cannot fit into the polymeric structure. (See
         <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">
          "Structure and function of normal hemoglobins", section on 'Oxygenation and deoxygenation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Promoting polymerization
         </strong>
         – Polymerization is enhanced by the following [
         <a href="#rid20">
          20,26
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Deoxygenation
         </strong>
         – The contact between the valine at amino acid 7 and the acceptor site in the partner strand is only possible when Hb S is in the T state; R state Hb S cannot fit into the polymeric structure. Hb S can undergo innumerable cycles of deoxygenation-induced polymerization and reoxygenation-induced depolymerization.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Higher Hb S concentration
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In adults who are homozygous for Hb S, Hb S can make up &gt;90 percent of all Hb, with approximately 3 percent Hb A2 and variable amounts of Hb F, or it can be as low as 80 percent if Hb F is greatly increased  (
         <a class="graphic graphic_table graphicRef116210" href="/z/d/graphic/116210.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In sickle-beta
         <sup>
          +
         </sup>
         thalassemia, mutations that produce fewer normal beta globin chains are associated with more severe disease because Hb S concentrations are higher, favoring polymerization.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The marked cellular dehydration seen in Hb SC RBCs increases the concentration of Hb S, favoring polymerization [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The virtual absence of vaso-occlusive complications and hemolysis in compound heterozygotes with gene deletion Hb S-HPFH (hereditary persistence of fetal hemoglobin) is due to pancellular levels of Hb F of approximately 30 percent, inhibiting Hb S polymerization [
         <a href="#rid29">
          29-31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">
          "Fetal hemoglobin (Hb F) in health and disease", section on 'Non-deletion HPFH'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Results of gene therapy trials that have resulted in &gt;40 percent Hb F or a Hb F-like Hb A have prevented new vaso-occlusive events and corrected hemolytic anemia. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Therapies with curative intent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cellular dehydration causes molecular crowding. Resulting increases in Hb S concentration are accentuated by membrane damage, creating a cycle of increased sickling. Because of crowding, Hb S can polymerize at higher than expected oxygen saturations. (See
         <a class="local">
          'Cellular dehydration'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hb D Los Angeles (
         <em>
          HBB
         </em>
         p.glu121gln) polymerizes much more readily than a solution containing only Hb S; the glu112gln substitution stabilizes the polymer [
         <a href="#rid32">
          32
         </a>
         ]. Compound heterozygotes for Hb S and Hb D Los Angeles have a severe clinical phenotype. (See
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb D'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acidosis
         </strong>
         –
         <strong>
         </strong>
         A decrease in blood pH below 7.4 in tissue capillaries yields twice the normal decrease in oxygen affinity and a large release of oxygen from red cells, significantly increasing their risk of sickling. Clinically, this means that even mild transient acidosis (with a corresponding drop of intracellular pH) could induce sickling, leading to further tissue hypoxia. The latter was unethically demonstrated when patients with sickle cell anemia were infused with low pH isotonic solutions and acute painful episodes ensued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reducing polymerization
         </strong>
         – Polymerization can be inhibited either directly or indirectly [
         <a href="#rid4">
          4,30,33
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Direct inhibition
         </strong>
         – Direct inhibition is achieved by the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Increasing Hb-oxygen affinity (decreasing deoxy-Hb S) with medications like
         <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">
          voxelotor
         </a>
         or by decreasing 2,3 BPG with therapies under development that activate pyruvate kinase. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Reducing Hb S polymerization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Increased Hb F occurs naturally with HPFH, or via therapeutic interventions. Hb F contains gamma chains, which are not incorporated into the polymer.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Increasing Hb A2. Hb A2 contains delta chains, which are not incorporated into the polymer.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indirect inhibition
         </strong>
         – Indirect inhibition is achieved by the following, both of which reduce the mean corpuscular hemoglobin concentration (MCHC):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Concomitant alpha thalassemia.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hydrating the sickle RBC using agents that inhibit cation and water loss.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4218215376">
         <span class="h2">
          Polymer structure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following a change that induces Hb S polymerization, there is a measurable lag time before a signal reflecting the presence of detectable polymer. The progress of polymer formation is exponential. Once the polymer nucleus is formed (homogeneous nucleation), subsequent addition of molecules is highly favored (heterogeneous nucleation) and fiber growth becomes very rapid (approximately 250 hemoglobin tetramers per second) [
         <a href="#rid34">
          34
         </a>
         ]. Hb S must be in the T quaternary conformation and must be unliganded for nucleation to occur [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         The Hb S polymer is made of seven twisted double Hb S tetramer strands, one in the center of the fiber surrounded by the other six. These fibers elongate and align with other polymerized Hb fibers forming bundles of fibers; these are nearly visible in a transmission electron micrograph (EM)  (
         <a class="graphic graphic_picture graphicRef61255" href="/z/d/graphic/61255.html" rel="external">
          picture 1
         </a>
         ). Longitudinal views reveal a subtle but regular helix structure [
         <a href="#rid36">
          36
         </a>
         ]. Parallel bundles of long fibers are oriented along the axis of sickling [
         <a href="#rid37">
          37-40
         </a>
         ]. These longitudinal polymer bundles give sickle cells their classic "sickle" shape and other highly variable shapes, as illustrated in the scanning EM  (
         <a class="graphic graphic_picture graphicRef77366" href="/z/d/graphic/77366.html" rel="external">
          picture 2
         </a>
         ). Several intermolecular and intramolecular interactions appear to be important in the polymer structure. X-ray diffraction studies subsequently refined the structure at a resolution of 0.2 nm (2.0 Å) and provided information on molecular orientation and contacts.
        </p>
        <p>
         In some RBCs, polymer is nucleated in several orientations. In cells that assume a holly leaf shape, bundles of Hb S fibers point in the direction of each projection. (See
         <a class="local">
          'Formation of sickled cells'
         </a>
         below.)
        </p>
        <p>
         Polymerized Hb S damages the RBC membrane, interfering with membrane function, cell deformability, and cell lifespan. (See
         <a class="local">
          'Effects on the RBC'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2581169187">
         <span class="h1">
          EFFECTS ON THE RBC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sickle fibers initiate a cascade of events that include damage to the red blood cell (RBC) membrane, cellular dehydration, deformation of the cell into a sickle shape, and hemolysis.
        </p>
        <p class="headingAnchor" id="H1133911526">
         <span class="h2">
          Membrane damage
         </span>
         <span class="headingEndMark">
          —
         </span>
         The RBC membrane can undergo reversible changes related to the Hb S polymer. Following deoxygenation, RBCs containing Hb S assume a variety of distorted shapes readily appreciated by light microscopy  (
         <a class="graphic graphic_picture graphicRef64449" href="/z/d/graphic/64449.html" rel="external">
          picture 3
         </a>
         ) and even more clearly by scanning electron microscopy  (
         <a class="graphic graphic_picture graphicRef77366" href="/z/d/graphic/77366.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         However, the membrane can only withstand a finite number of these cycles before it is irreversibly injured and the abnormal cell shape becomes irreversible. The accumulation of membrane damage ultimately renders cells irreversibly sickled regardless of the physical state of their Hb molecules, which may be in solution [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Sickle cells appearing on blood films are irreversibly sickled cells (ISCs) [
         <a href="#rid43">
          43
         </a>
         ]. Their numbers remain generally constant over time but decrease early in acute vaso-occlusive episodes, while dense cell numbers increase. Later in the acute vaso-occlusive event, dense cells rebound to levels higher than in the steady state, while ISCs mostly disappear.
        </p>
        <p>
         Cell membrane damage can cause release of vesicles and membrane particles, which have been linked to increased endothelial adhesivity and hypercoagulability. (See
         <a class="local">
          'Adhesion of sickled cells to the vascular endothelium'
         </a>
         below and
         <a class="local">
          'Hypercoagulable state'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RBC microparticles can be derived from reticulocytes and mature RBCs, and they can take several different forms. Large right-side-out particles display phosphatidylserine, which is prothrombotic [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microparticles derived from sickle RBCs increased neutrophil adhesion to cultured endothelial cells, along with increased levels of messenger RNA and protein for intercellular adhesion molecule-1 (ICAM-1), an effect that was reduced when microparticles were isolated from hydroxyurea-treated patients and increased when microparticles were isolated during acute painful episodes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microparticles might affect pathophysiology by triggering a proinflammatory phenotype [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2231646760">
         <span class="h2">
          Cellular dehydration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polymerized Hb fibers interact with cell membranes and activate volume-regulating transport systems, leading to RBC dehydration [
         <a href="#rid46">
          46,47
         </a>
         ]. Sickle RBCs can be rigid, poorly deformable, and fragile due to the presence of Hb S polymer alone.
        </p>
        <p>
         This dehydration of sickle RBCs involves increased activity of the membrane K-Cl cotransporter, the calcium-dependent (Gardos) potassium channel, and mechanosensitive channels such as Piezo-1 [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7091.html" rel="external">
          "Red blood cell membrane: Structure and dynamics", section on 'Piezo-1'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'KCNN4 (Gardos channel gene)'
         </a>
         .)
        </p>
        <p>
         Increasing density adversely affects RBCs by increasing the concentration of Hb S, which in turn fosters polymerization and downstream consequences [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="local">
          'Hb S polymerization and fiber formation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Formation of sickled cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hb S polymer distorts and damages the RBC. Mature RBCs and reticulocytes can accumulate polymerized hemoglobin and form sickled cells, whereas immature, nucleated RBC precursor cells do not sickle [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
         Sickled cells are dense, dehydrated, fragile cells with limited deformability that likely impairs their ability to traverse the microcirculation [
         <a href="#rid53">
          53
         </a>
         ]. However, simple mechanical obstruction of vessels by misshapen cells is not considered the principal mechanism of vaso-occlusion. (See
         <a class="local">
          'Vaso-occlusion'
         </a>
         below.)
        </p>
        <p>
         The majority (perhaps 95 percent) of cells do not contain measurable polymer during their flow through arterioles and capillaries [
         <a href="#rid54">
          54
         </a>
         ]. In contrast, if these cells were equilibrated at the oxygen tensions in the microcirculation, virtually all of them would contain polymer and as a result would have markedly decreased deformability. Thus, kinetics is the critical determinant of cell shape and morphology [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Vascular obstruction'
         </a>
         below.)
        </p>
        <p>
         The classic sickle shape that occurs with slow deoxygenation is due to homogeneous nucleation in which one domain propagates by fiber growth and alignment to distort the cell into an elongated shape. With somewhat more rapid deoxygenation, a few independent domains of heterogenous polymer nucleation will induce a more irregular shape [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Formation of other shapes depends on the kinetics of Hb S polymerization, which in turn depends on the delay time in the microcirculation where deoxygenation occurs [
         <a href="#rid23">
          23,54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Holly leaf" cells form when different fibers are aligned in different orientations. Because the shape of the sickle cell depends on the number of independent polymer domains, it is possible to convert a holly leaf cell into an elongated sickle shape by partial reoxygenation [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="local">
          'Polymer structure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When deoxygenation is rapid, multiple spherulitic domains result in a granular or cobblestone texture ("sack of potatoes" aspect) with no gross distortion of cell shape.
        </p>
        <p>
        </p>
        <p>
         The distortion of cell shape by projections of aligned Hb S fibers plays a critical role in the pathogenesis of the membrane lesion. (See
         <a class="local">
          'Membrane damage'
         </a>
         above.)
        </p>
        <p>
         Sickle RBCs can hemolyze and precipitate vascular occlusion. (See
         <a class="local">
          'Hemolysis'
         </a>
         below and
         <a class="local">
          'Vaso-occlusion'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H110556111">
         <span class="h1">
          HEMOLYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaso-occlusion and hemolytic anemia are actually interrelated, as both are consequences of Hb S polymerization and red blood cell (RBC) damage. For example, reticulocytes, greatest in number in patients with the most severe hemolysis, are thought to be the cells that might initiate vaso-occlusion.
        </p>
        <p class="headingAnchor" id="H3542998805">
         <span class="h2">
          Sites of RBC destruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sickle cells undergo intravascular and extravascular hemolysis, both of which contribute to anemia and increased RBC turnover, with a high percentage of reticulocytes. Approximately two-thirds of hemolysis is extravascular and one-third is intravascular. The intravascular hemolysis component varies among patients as a result of differences in the RBC distribution of Hb F and Hb S concentrations and cellular hydration.
        </p>
        <p>
         The best biomarker for hemolysis is RBC lifespan. The percentage of reticulocytes and the Hb F level correlate strongly with the RBC lifespan; in contrast, the Hb and hematocrit are not correlated RBC lifespan [
         <a href="#rid57">
          57
         </a>
         ]. Irreversibly sickled cells (ISCs) have a short survival, and their numbers reflect the rate of hemolysis [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Hemolytic anemia occurs continuously, even in the absence of clinically apparent acute vaso-occlusive events. Patients with the most severe anemia have fewer acute vaso-occlusive events, but they have increased mortality and more chronic organ damage [
         <a href="#rid59">
          59
         </a>
         ]. Higher rates of hemolysis with nitric oxide (NO) scavenging might cause progressive vascular damage. (See
         <a class="local">
          'Clinical consequences and therapeutic implications of SCD pathophysiology'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravascular
         </strong>
         — Intravascular hemolysis releases free heme and other cellular contents including arginase and lactate dehydrogenase (LDH) into the circulation. Arginase degrades arginine, the substrate of the NO synthases; LDH is one measure of intravascular hemolysis in SCD. Downstream effects of intravascular hemolysis include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Generation of reactive oxygen species
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Scavenging of NO [
         <a href="#rid60">
          60
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Generation of carbon monoxide (CO) from heme catabolism [
         <a href="#rid20">
          20,26
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endothelial damage [
         <a href="#rid61">
          61,62
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Interference with the ability of ADAMTS13 to cleave large von Willebrand factor multimers [
         <a href="#rid63">
          63
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Activation of neutrophils and formation of neutrophil extracellular traps (NETs) [
         <a href="#rid64">
          64
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extravascular
         </strong>
         – Extravascular hemolysis occurs in macrophages of the reticuloendothelial system in the liver, spleen (when still intact), and bone marrow.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4086857817">
         <span class="h2">
          Organ system effects of hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following subphenotypes of SCD are associated with high levels of hemolysis (gauged indirectly by bilirubin levels, reticulocyte count, LDH, and RBC microparticles):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leg ulcers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Priapism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney disease/albuminuria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stroke and increased transcranial Doppler (TCD) flow velocity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperbilirubinemia/cholelithiasis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary hypertension (PH)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased tricuspid regurgitant jet velocity on echocardiography, associated with PH
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mortality
        </p>
        <p>
        </p>
        <p>
         The mechanisms of these effects are incompletely understood and likely multifactorial, and they may differ depending on the specific organ system.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efferocytosis
         </strong>
         – Efferocytosis refers to phagocytosis of apoptotic cells by macrophages; it is important in resolving tissue injury. (See
         <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">
          "An overview of the innate immune system", section on 'Efferocytosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A study using mouse models and in vitro assays demonstrated that macrophages from sickle cell mice had impaired efferocytosis, resulting in accumulation of damaged cells in the liver and increased hepatic transaminases [
         <a href="#rid65">
          65
         </a>
         ]. The effect of free heme on macrophage reprogramming may contribute to sickle hepatopathy [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3589.html" rel="external">
          "Hepatic manifestations of sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nitric oxide
         </strong>
         – In addition to its vasodilatory activity, NO also modulates hemoglobin function, blocks the activation of platelets, and attenuates the adhesivity of endothelial cells for sickle cells [
         <a href="#rid67">
          67-69
         </a>
         ].The apparently limited bioavailability of NO in SCD may be related to depleted stores of the NO precursor L-arginine, sequestration of plasma NO by free hemoglobin, oxidative inactivation of NO, increased levels of arginase, or failure to deliver NO to the RBC membrane [
         <a href="#rid70">
          70-77
         </a>
         ]. Such loss of NO regulation, associated especially with high degrees of intravascular hemolysis, has been associated with endothelial dysfunction and end-organ vasculopathy including leg ulcers, nephropathy, priapism, PH, and death [
         <a href="#rid73">
          73,78,79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Sickle cells loaded in vitro with NO and reoxygenated exhibited decreased epinephrine-activated cell adhesion to endothelium, decreased ability to mediate leukocyte adhesion in vitro, and decreased vessel obstruction in vivo [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1181945942">
         <span class="h2">
          Effects of concomitant alpha thalassemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many populations with SCD have high rates of concomitant alpha globin gene deletions that cause alpha thalassemia (30 to &gt;60 percent of individuals). The most common gene deletion removes a 3.7 kb fragment that leaves one functional alpha globin gene/chromosome intact. Patients can be either heterozygous (a deletion on one chromosome) or homozygous (a deletion on both chromosomes). (See
         <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">
          "Diagnosis of thalassemia (adults and children)", section on 'Alpha thalassemias'
         </a>
         .)
        </p>
        <p>
         Alpha thalassemia modulates SCD by reducing the intracellular concentration of Hb S. This decreases Hb S polymer-induced cellular damage, which ameliorates hemolysis. Concomitant alpha thalassemia is usually associated with fewer complications related to hemolysis such as those listed above. (See
         <a class="local">
          'Hemolysis'
         </a>
         above.)
        </p>
        <p>
         Hematologic and laboratory characteristics in SCD-alpha thalassemia include average Hb levels of 9 to 10 g/dL, an increase in Hb A2 to approximately 4 percent (which is due to post-translational mechanisms), microcytosis, and less evidence of hemolysis compared with individuals without concomitant alpha thalassemia (lower reticulocyte count, bilirubin, and LDH, and fewer dense cells and ISCs); RBC lifespan is increased. Individuals with homozygous alpha thalassemia have more pronounced hematologic changes and reductions in hemolysis than individuals who are heterozygous for alpha thalassemia.
        </p>
        <p>
         However, individuals with concomitant SCD and alpha thalassemia have comparable or perhaps increased rates of acute vaso-occlusive events (painful episodes, acute chest syndrome). This has been ascribed to increased blood viscosity that results from their higher Hb levels [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         Microcytosis increases intracellular levels of Hb A2. SCD-alpha thalassemia is a phenocopy of Hb S-beta
         <sup>
          0
         </sup>
         thalassemia and is very difficult to distinguish without genetic testing [
         <a href="#rid82">
          82
         </a>
         ]. The clinician should take care to establish the correct genetic diagnosis before providing genetic counseling for individuals designated as having Hb S-beta
         <sup>
          0
         </sup>
         thalassemia based solely on a protein-based method of analysis such as high-performance liquid chromatography (HPLC) or electrophoresis [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7115.html" rel="external">
          "Overview of compound sickle cell syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          VASO-OCCLUSION
         </span>
        </p>
        <p class="headingAnchor" id="H3252378913">
         <span class="h2">
          Vascular obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         A common assumption is that the pathophysiology of SCD involves only microvascular obstruction. This is based on the expectation that the smallest vessels should be most susceptible to vaso-occlusion. However, studies in animal models and in humans have identified several sites of impaired blood flow and vaso-occlusion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large arteries of SCD patients with stroke [
         <a href="#rid83">
          83
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small vessels [
         <a href="#rid84">
          84
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arteriolar-capillary bifurcations and venular junctions [
         <a href="#rid85">
          85
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Capillaries [
         <a href="#rid86">
          86-88
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Post-capillary venules [
         <a href="#rid86">
          86,89
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         This variation may be due to the kinetics of polymerization, which includes a delay time between the generation of deoxy-Hb S and polymer formation, resulting in a delay in cell sickling until they have passed into a vessel too large to be occluded by a few sickled cells [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         It seems reasonable that the initiation of vaso-occlusion varies over time and place according to differences in blood shear rates and endothelial activation states, vascular bed characteristics, vascular tone, differential responses to endothelial cell agonists, and varying expression of cellular and soluble adhesion molecules [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         However, vaso-occlusive complications in SCD are unlikely to be due to simple vascular obstruction by sickled cells, as was previously thought. Rather, sickle cells may adhere to the vascular endothelium and induce changes that lead to vaso-occlusion, with sickled cells accumulating proximal to the initial site of adherence ("log-jamming") after other changes cause occlusion. These initial vascular changes include endothelial damage, inflammation, and vasoconstriction.
        </p>
        <p>
         The initiation of vaso-occlusion is a complex, highly stochastic process. The mechanism involves several events including changes in RBC volume, shape, and membrane properties, leading to increased RBC adherence to the endothelium, along with vasoconstriction, inflammatory changes, and likely other changes that remain incompletely understood [
         <a href="#rid86">
          86,91,92
         </a>
         ]. (See
         <a class="local">
          'Adhesion of sickled cells to the vascular endothelium'
         </a>
         below.)
        </p>
        <p>
         Contributing mechanisms to vaso-occlusion are summarized in the table  (
         <a class="graphic graphic_table graphicRef74933" href="/z/d/graphic/74933.html" rel="external">
          table 2
         </a>
         ). Details and supporting studies are discussed below.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Adhesion of sickled cells to the vascular endothelium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Profound differences are present among endothelial cells isolated from different organs, perhaps accounting for some of the organ specificity of vaso-occlusive events [
         <a href="#rid93">
          93,94
         </a>
         ]. In a 1980 report, abnormal adhesivity of sickle RBCs to endothelium was documented in vitro and in vivo, and it appeared to correlate with disease severity [
         <a href="#rid95">
          95
         </a>
         ]. Ischemia-reperfusion-induced injury can extend the vaso-occlusion-initiated tissue damage [
         <a href="#rid96">
          96,97
         </a>
         ].
        </p>
        <p>
         Some of the cellular findings are depicted in the figures illustrating adhesion of sickled cells to the vasculature  (
         <a class="graphic graphic_figure graphicRef57423" href="/z/d/graphic/57423.html" rel="external">
          figure 4
         </a>
         ) and subsequent trapping of denser cells  (
         <a class="graphic graphic_figure graphicRef80615" href="/z/d/graphic/80615.html" rel="external">
          figure 5
         </a>
         ). In studies of human sickle cells perfused into rat vessels, the more adhesive, low density sickled cells such as reticulocytes adhered to the vascular endothelium to initiate occlusion, and poorly deformable, dense cells become trapped in the regions of cell adhesion [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         Examples of contributing mechanisms include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Circulating factors
         </strong>
         – Cytokines, chemokines, histamine, thrombin, and heme have been implicated in endothelial adherence and endothelial cell activation [
         <a href="#rid98">
          98-105
         </a>
         ]. Blood cells including activated monocytes and platelets may also contribute [
         <a href="#rid106">
          106,107
         </a>
         ]. Adhesion is also increased by epinephrine [
         <a href="#rid108">
          108-110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Soluble adhesion markers (soluble ICAM-1, E-selectin, and VCAM-1) were elevated in patients with SCD, signifying endothelial dysfunction or inflammation with endothelial activation; the degree of elevation correlated with the severity of pulmonary hypertension and risk of death, although these are poor prognostic markers in individual patients [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Microparticles containing RBC membrane, released following membrane damage, may also contribute. (See
         <a class="local">
          'Membrane damage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adhesion molecules
         </strong>
         – Adhesion molecules on endothelial cells and the adhesion of sickle cells (reticulocytes and mature RBCs) to these molecules has been the subject of considerable investigation [
         <a href="#rid112">
          112-115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endothelial cells express P-selectin upon hypoxic or ischemia/reperfusion injury [
         <a href="#rid116">
          116-118
         </a>
         ]. Preclinical models support a role for P-selectin in binding of sickle cells to endothelial cells [
         <a href="#rid119">
          119-122
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mouse models also suggest that E-selectin could increase vaso-occlusion [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infection or inflammation might initiate vaso-occlusion via expression of adhesion molecules [
         <a href="#rid124">
          124-128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complement components may also play a role [
         <a href="#rid129">
          129,130
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">
          "Complement pathways"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endothelial cells in different organs and different vascular beds appear to express different combinations of adhesion molecules [
         <a href="#rid131">
          131
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1330.html" rel="external">
          "The endothelium: A primer", section on 'Endothelial heterogeneity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">
          Crizanlizumab
         </a>
         , a P-selectin-blocking antibody, decreased acute vaso-occlusive events and is approved for treatment. (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease", section on 'Decreasing cell adhesion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         There appears to be an inverse correlation between the severity of hemolysis and vaso-occlusive events. A reduction in the frequency of vaso-occlusive events in individuals with more severe hemolysis might be a result of lower blood viscosity associated with more severe anemia. (See
         <a class="local">
          'Hemolysis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Vasoconstriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasoregulatory factors probably influence vaso-occlusion by affecting flow velocity and the microcirculatory transit time. These effects could initiate or contribute to the evolution of vaso-occlusion already in progress [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
         Contributing factors may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoxia
         </strong>
         – Hypoxia induces vasoconstriction via factors such as endothelin (ET-1) and placental growth factor [
         <a href="#rid133">
          133-139
         </a>
         ]. In most acute vaso-occlusive events, there is no evidence of preceding hypoxia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NO
         </strong>
         – Effects of NO on SCD physiology are complex. In addition to its role in vasodilation, NO blocks platelet activation and attenuates the adhesivity of the endothelium for sickle cells; vasoconstriction might be affected by its reduced bioavailability [
         <a href="#rid59">
          59,140
         </a>
         ]. Reduced NO occurs when hemolysis releases from heme, which is an NO scavenger. (See
         <a class="local">
          'Hemolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         The vasoregulatory actions of catecholamines might be a potential component of the association between vaso-occlusive pain events and "stress." Epinephrine-activated sickle erythrocytes also induce lymphocyte and monocyte adherence to the endothelium [
         <a href="#rid141">
          141
         </a>
         ]. (See
         <a class="local">
          'Stress or stress hormones'
         </a>
         below.)
        </p>
        <p>
         Reduced blood flow in response to temperature, especially cold, was ascertained by plethysmography and found to be greater in people with SCD than in controls [
         <a href="#rid142">
          142
         </a>
         ]. Individuals with higher anxiety also experienced more rapid vasoconstriction. Augmented vasoconstrictive responses and progressive decreases in perfusion with repeated thermal stimulation in SCD were indicative of autonomic hypersensitivity in the microvasculature.
        </p>
        <p>
         Nocturnal vasoconstriction, measured during polysomnography in 212 children and adolescents with SCD, was predictive of subsequent acute painful events [
         <a href="#rid143">
          143
         </a>
         ]. The role of the autonomic nervous system in the control of the microvasculature has been reviewed [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory changes mediated by white blood cells (WBCs) and mast cells likely contribute to vaso-occlusion, but the therapeutic use of anti-inflammatory agents has not been demonstrated to reduce complications. In a study of 70 children with SCD, high-sensitivity C-reactive protein (hsCRP) levels, a marker of low-grade systemic inflammation, emerged as the most significant laboratory correlate of hospitalization for pain or vaso-occlusive events [
         <a href="#rid145">
          145
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutrophils
         </strong>
         – There is a correlation between high WBC count and rates of pain, hemorrhagic stroke, and mortality in SCD, although this may represent an association with other aspects of disease biology and may not be causally related [
         <a href="#rid146">
          146,147
         </a>
         ]. Some have suggested that
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         might improve vaso-occlusive events by decreasing neutrophil counts; however, dosing is titrated based on neutrophil counts, making this challenging to evaluate. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Other mechanisms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Administration of granulocyte colony-stimulating factor (G-CSF) to patients with SCD has resulted in extreme leukocytosis followed by severe vaso-occlusive events, some fatal [
         <a href="#rid148">
          148
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Avoidance of G-CSF'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mechanisms by which neutrophils might foster vaso-occlusion are incompletely understood. Neutrophils are less deformable than RBCs and do not pass through the microvasculature as easily [
         <a href="#rid149">
          149
         </a>
         ]. Neutrophils from individuals with SCD show enhanced expression of oxidant and antiinflammatory genes relative to controls [
         <a href="#rid150">
          150
         </a>
         ]. Neutrophils bound to the endothelium might provide a nidus of adhesion to allow RBCs to adhere to the vasculature in areas of low flow or to take longer to transit through a low oxygen region and sickle [
         <a href="#rid90">
          90,110,141,151-154
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monocytes
         </strong>
         – SCD patients have greater numbers of patrolling monocytes with high heme-oxygenase (HO)-1 expression compared with controls [
         <a href="#rid155">
          155
         </a>
         ]. Individuals with a recent vaso-occlusive episode had lower numbers of these patrolling monocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mast cells
         </strong>
         – Mast cell-derived cytokines may contribute to neurogenic inflammation and nociceptive pain (pain associated with inflammation). (See
         <a class="medical medical_review" href="/z/d/html/3979.html" rel="external">
          "Mast cells: Development, identification, and physiologic roles"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytokines and other inflammatory mediators
         </strong>
         – In sickle mice, C5a, a proinflammatory mediator, promotes inflammation and vaso-occlusion [
         <a href="#rid156">
          156
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3967.html" rel="external">
          "Regulators and receptors of the complement system", section on 'C5a receptor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Antiinflammatory therapies, including intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), statins, and mast cell inhibitors, had some benefits in sickle mice and in limited observations in patients, but these therapies are not a component of routine care. [
         <a href="#rid157">
          157-159
         </a>
         ]
        </p>
        <p>
         When used to treat acute vaso-occlusive events, glucocorticoids were associated with an increased rate of hospital readmission, and among &gt;5000 patients of all ages, glucocorticoid exposure was associated with increased likelihood of hospitalization for a vaso-occlusive episode (OR 3.8, CI 2.4-5.6) [
         <a href="#rid160">
          160,161
         </a>
         ].
        </p>
        <p>
         In a randomized trial in 49 individuals with SCD and elevated hsCRP who were receiving
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , patients assigned to receive
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         , an inhibitor of the proinflammatory cytokine interleukin (IL)-1beta, or placebo over 24 weeks, canakinumab reduced hospitalization, vaso-occlusive episodes, and fatigue, although it did not significantly reduce daily pain [
         <a href="#rid162">
          162
         </a>
         ]. Reductions were observed in some markers of inflammation (hsCRP and WBC count) but not others (VCAM-1, P-selectin, or IL-8).
        </p>
        <p class="headingAnchor" id="H239840005">
         <span class="h2">
          Other contributing factors
         </span>
        </p>
        <p class="headingAnchor" id="H213621643">
         <span class="h3">
          Increased blood viscosity
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the hematocrit of sickle cell blood is increased in vitro, even with the addition of non-sickle RBCs, blood viscosity is increased and blood flow properties are impaired [
         <a href="#rid163">
          163
         </a>
         ]. This phenomenon provides the basis for the recommendation to avoid post-transfusion hemoglobin &gt;10 g/dL when the hemoglobin S level is greater than 50 percent [
         <a href="#rid164">
          164,165
         </a>
         ]. However, in practice when the hemoglobin S levels are &lt;20 percent, the total hemoglobin can be increased to approximately 12 g/dL with less concern for hyperviscosity syndrome [
         <a href="#rid163">
          163
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Risk of hyperviscosity syndrome from simple transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1489597230">
         <span class="h3">
          Stress or stress hormones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mental stress (or even anticipation of a stressful event) causes vasoconstriction; this is true in individuals with and without SCD [
         <a href="#rid166">
          166-168
         </a>
         ]. Stress hormones may increase pain by increasing vasoconstriction and autonomic nervous system reactivity. (See
         <a class="local">
          'Vasoconstriction'
         </a>
         above.)
        </p>
        <p>
         Epinephrine may enhance adhesivity of sickle RBCs, lymphocytes, and monocytes to the vascular wall [
         <a href="#rid108">
          108,110,141
         </a>
         ].
        </p>
        <p>
         Psychosocial support, treatment of insomnia, and antidepressant therapy for individuals with depression are an important supplement to analgesia in management and prevention. (See
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease", section on 'Adjuvant therapies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2691402946">
         <span class="h1">
          HYPERCOAGULABLE STATE
         </span>
         <span class="headingEndMark">
          —
         </span>
         SCD is a hypercoagulable state with multifactorial mechanisms. Contributing factors may include [
         <a href="#rid169">
          169-173
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induction of inflammatory cytokines
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microparticles derived from RBC membranes (see
         <a class="local">
          'Membrane damage'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endothelial dysfunction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cyto-adhesive proteins mediating RBC adherence to the endothelium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ischemia-reperfusion injury
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expression of tissue factor on circulating monocytes or microparticles
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activated factor XII
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelet activation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activation of coagulation pathways and thrombin generation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Free heme from intravascular hemolysis, leading to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Generation of oxygen-free radicals
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vasoconstriction due to NO depletion
        </p>
        <p>
        </p>
        <p>
         Endothelial NO diffuses to smooth muscle, where it binds and activates the heme of soluble guanylate cyclase, which converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) and produces vasodilation by smooth muscle relaxation. NO depletion is a result of RBC release of heme into plasma. Heme reacts with NO via the dioxygenation reaction forming inert nitrate. NO is further depleted by its reaction with reactive oxygen species and by the destruction of arginine by arginase. Endothelial changes are discussed separately in more detail. (See
         <a class="medical medical_review" href="/z/d/html/1330.html" rel="external">
          "The endothelium: A primer", section on 'Procoagulant properties'
         </a>
         .)
        </p>
        <p>
         Venous thromboembolism (VTE) is a common complication of SCD. Up to 12 percent of patients have had a thromboembolic event by age 40 years, although rates twice as high have been reported [
         <a href="#rid174">
          174
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">
          "Overview of the clinical manifestations of sickle cell disease", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
         VTE prophylaxis is appropriate in most adults with SCD hospitalized with an acute medical illness. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'
         </a>
         .)
        </p>
        <p>
         VTE treatment is similar to individuals without SCD.
        </p>
        <p class="headingAnchor" id="H2406479463">
         <span class="h1">
          CLINICAL CONSEQUENCES AND THERAPEUTIC IMPLICATIONS OF SCD PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaso-occlusion and hemolysis both contribute to the phenotypes of SCD. Clinical manifestations according to organ system are discussed in separate topic reviews listed above. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
         If possible, therapies for SCD should reduce vaso-occlusion and hemolysis, as exemplified by the effects of inducing high levels of Hb F.
        </p>
        <p>
         As they are slow to develop, the beneficial effects of reduced hemolysis on pulmonary and systemic vascular disease might take many years to become apparent.
        </p>
        <p>
         If interventions only reduce hemolysis, then vaso-occlusive complications may not improve. This is suggested by the natural history of concomitant SCD with alpha thalassemia and the findings from a clinical trial of senicapoc, in which reduction of hemolysis did not decrease vaso-occlusive events [
         <a href="#rid175">
          175
         </a>
         ].
        </p>
        <p>
         The mechanisms of various interventions, approved and investigational, are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">
          "Disease-modifying therapies to prevent pain and other complications of sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H990381536">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">
          "Patient perspective: Sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hb S
         </strong>
         – The genetic variant that produces sickle hemoglobin (Hb S) is a point mutation in the
         <em>
          HBB
         </em>
         gene, which encodes beta globin chains
         <em>
         </em>
         (
         <a class="graphic graphic_figure graphicRef65642" href="/z/d/graphic/65642.html" rel="external">
          figure 1
         </a>
         ); it results in substitution of valine for glutamic acid at amino acid 7 (glu7val; previously designated as glu6val). Sickle cell disease (SCD) occurs when Hb S is present in the homozygous state (sometimes designated Hb SS) or in compound heterozygosity with certain other
         <em>
          HBB
         </em>
         variants (Hb C, D, or E), or with beta thalassemia  (
         <a class="graphic graphic_figure graphicRef131447" href="/z/d/graphic/131447.html" rel="external">
          figure 2
         </a>
         ). Other gene variation can contribute to SCD severity. As an example, variants that increase Hb F production reduce the likelihood and severity of SCD complications. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hb S polymerization
         </strong>
         – Hb S can polymerize when in the deoxygenated state. This is the primary, indispensable, initiating pathophysiologic event in SCD. Polymerization is increased by higher Hb S concentrations, increased 2,3 BPG, and acidosis. (See
         <a class="local">
          'Hb S polymerization and fiber formation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RBC changes
         </strong>
         – Polymerized Hb S can cause red blood cell (RBC) membrane damage, which leads to cellular dehydration. This in turn further concentrates Hb S and increases cell sickling  (
         <a class="graphic graphic_picture graphicRef61255" href="/z/d/graphic/61255.html" rel="external">
          picture 1
         </a>
         ). Abnormal RBC morphologies include the classic sickle cell shape  (
         <a class="graphic graphic_picture graphicRef77366" href="/z/d/graphic/77366.html" rel="external">
          picture 2
         </a>
         ) and others  (
         <a class="graphic graphic_picture graphicRef64449" href="/z/d/graphic/64449.html" rel="external">
          picture 3
         </a>
         ). (See
         <a class="local">
          'Effects on the RBC'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolysis
         </strong>
         – SCD is associated with continuous intravascular and extravascular hemolysis. Intravascular hemolysis releases free heme, which scavenges nitric oxide (NO), impairs phagocytosis of dead cells, and further increases vasoconstriction and inflammation. Hemolysis correlates with several SCD complications (leg ulcers, kidney disease, hypertension, stroke, pulmonary hypertension, cholelithiasis, and death). (See
         <a class="local">
          'Hemolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaso-occlusion
         </strong>
         – Many interrelated processes contribute to the pathophysiology of vaso-occlusion, as summarized in the table  (
         <a class="graphic graphic_table graphicRef74933" href="/z/d/graphic/74933.html" rel="external">
          table 2
         </a>
         ). Circulating factors (cytokines, chemokines, histamine, thrombin, heme) and adhesion molecules (selectins, complement components) contribute significantly to the initial adhesion of sickle RBCs to the vascular endothelium. Hypoxia and reduced bioavailability of NO contribute to vasoconstriction. Inflammation, increased blood viscosity, and stress hormones may exacerbate vaso-occlusion. All types of vessels can be involved. (See
         <a class="local">
          'Vaso-occlusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic implications
         </strong>
         – Approved therapies for SCD and new agents under investigation target different features of pathophysiology. Therapies that target Hb polymerization directly (
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         or gene therapy) are the most efficacious. (See
         <a class="local">
          'Clinical consequences and therapeutic implications of SCD pathophysiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">
          "Disease-modifying therapies to prevent pain and other complications of sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110324.html" rel="external">
          "Investigational therapies for sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3165728988">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Shriner D, Rotimi CN. Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase. Am J Hum Genet 2018; 102:547.
          </a>
         </li>
         <li class="breakAll">
          Steinberg MH. Other sickle hemogloniopathies. In: Disorders of Hemoglobin, 2nd ed, Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (Eds), Cambridge Univ Press, 2009. p.564.
         </li>
         <li class="breakAll">
          Schechter AN, Noguchi CT. Sickle hemoglobin polymerization: Structure-function correlates. In: Sickle cell disease: Basic principles and clinical practice, Embury SH, Hebbel RP, Mohandas N, et al (Eds), Raven, 1994. p.902.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979; 76:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Gardner K, Tegegn MB, et al. Genetic variants of PKLR are associated with acute pain in sickle cell disease. Blood Adv 2022; 6:3535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen-Solal M, Préhu C, Wajcman H, et al. A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry). Br J Haematol 1998; 103:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med 2017; 376:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol 2019; 14:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med 2021; 384:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esrick EB, Lehmann LE, Biffi A, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med 2021; 384:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanter J, Walters MC, Krishnamurti L, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med 2022; 386:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swerdlow PH, Bryan RA, Bertles JF, et al. Effect of 2, 3-diphosphoglycerate on the solubility of deoxy-sickle hemoglobin. Hemoglobin 1977; 1:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poillon WN, Kim BC. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 1990; 76:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunn HF. The interaction of sickle hemoglobin with DPG, CO 2 and with other hemoglobins: formation of asymmetrical hybrids. Adv Exp Med Biol 1972; 28:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill SJ, Skold R, Fall L, et al. Aggregation effects on oxygen binding of sickle cell hemoglobin. Science 1978; 201:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benesch RE, Edalji R, Kwong S, Benesch R. Oxygen affinity as an index of hemoglobin S polymerization: a new micromethod. Anal Biochem 1978; 89:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill SJ, Benedict RC, Fall L, et al. Oxygen binding to sickle cell hemoglobin. J Mol Biol 1979; 130:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sunshine HR, Hofrichter J, Ferrone FA, Eaton WA. Oxygen binding by sickle cell hemoglobin polymers. J Mol Biol 1982; 158:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross PD, Hofrichter J, Eaton WA. Thermodynamics of gelation of sickle cell deoxyhemoglobin. J Mol Biol 1977; 115:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross PD, Hofrichter J, Eaton WA. Calorimetric and optical characterization of sickle cell hemoglobin gelation. J Mol Biol 1975; 96:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magdoff-Fairchild B, Poillon WN, Li T, Bertles JF. Thermodynamic studies of polymerization of deoxygenated sickle cell hemoglobin. Proc Natl Acad Sci U S A 1976; 73:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990; 40:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987; 70:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briehl RW. Sickle-cell hemoglobin. Encyclopedia of Human Biology 1991; 7:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galamba N. On the Nonaggregation of Normal Adult Hemoglobin and the Aggregation of Sickle Cell Hemoglobin. J Phys Chem B 2019; 123:10735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueda Y, Nagel RL, Bookchin RM. An increased Bohr effect in sickle cell anemia. Blood 1979; 53:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunn HF, Noguchi CT, Hofrichter J, et al. Molecular and cellular pathogenesis of hemoglobin SC disease. Proc Natl Acad Sci U S A 1982; 79:7527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabry ME, Kaul DK, Raventos-Suarez C, et al. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences. J Clin Invest 1982; 70:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CONLEY CL, WEATHERALL DJ, RICHARDSON SN, et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 1963; 21:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem 1977; 252:3414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sewchand LS, Johnson CS, Meiselman HJ. The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes. Blood Cells 1983; 9:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adachi K, Kim J, Ballas S, et al. Facilitation of Hb S polymerization by the substitution of Glu for Gln at beta 121. J Biol Chem 1988; 263:5607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bookchin RM, Nagel RL, Balazs T. Role of hybrid tetramer formation in gelation of haemoglobin S. Nature 1975; 256:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuel RE, Salmon ED, Briehl RW. Nucleation and growth of fibres and gel formation in sickle cell haemoglobin. Nature 1990; 345:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yosmanovich D, Rotter M, Aprelev A, Ferrone FA. Calibrating Sickle Cell Disease. J Mol Biol 2016; 428:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dykes GW, Crepeau RH, Edelstein SJ. Three-dimensional reconstruction of the 14-filament fibers of hemoglobin S. J Mol Biol 1979; 130:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White JG. The fine structure of sickled hemoglobin in situ. Blood 1968; 31:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertles JF, Döbler J. Reversible and irreversible sickling: a distinction by electron microscopy. Blood 1969; 33:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edelstein SJ, Telford JN, Crepeau RH. Structure of fibers of sickle cell hemoglobin. Proc Natl Acad Sci U S A 1973; 70:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dykes G, Crepeau RH, Edelstein SJ. Three-dimensional reconstruction of the fibres of sickle cell haemoglobin. Nature 1978; 272:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White JG. Ultrastructural features of erythrocyte and hemoglobin sickling. Arch Intern Med 1974; 133:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant GR, Petch MC, Serjeant BE. The in vivo sickle phenomenon: a reappraisal. J Lab Clin Med 1973; 81:850.
          </a>
         </li>
         <li class="breakAll">
          Ballas SK, Eckman JR. Chapter 20: Sickle cell pain: biology, etiology, and treatment. In: Disorders of hemoglobin, 2nd ed, Steinberg MH, Forget BG, Higgs DR, Weatherall DJ (Eds), Cambridge Univ Press, Cambridge 2009. p.564.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RA, Mankelow TJ, Drizou D, et al. Large red cell-derived membrane particles are major contributors to hypercoagulability in sickle cell disease. Sci Rep 2021; 11:11035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnier Y, Ferdinand S, Garnier M, et al. Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties. Blood 2020; 136:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canessa M. Red cell volume-related ion transport systems in hemoglobinopathies. Hematol Oncol Clin North Am 1991; 5:495.
          </a>
         </li>
         <li class="breakAll">
          Brugnara C. Red Cell Membrane pathology in sickle cells. In: Disorders of Hemoglobin: Genetics, pathophysiology, clinical management, Steinberg MH, Forget BG, Higgs D, Nagel RL (Eds), Cambridge University Press, 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher PG. Disorders of red cell volume regulation. Curr Opin Hematol 2013; 20:201.
          </a>
         </li>
         <li class="breakAll">
          Brugnara C. Red cell membrane in sickle cell disease. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. p.550.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grasso JA, Sullivan AL, Sullivan LW. Ultrastructural studies of the bone marrow in sickle cell anaemia. II. The morphology of erythropoietic cells and their response to deoxygenation in vitro. Br J Haematol 1975; 31:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiuchi K, Onyike AE, Osterhout ML. Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension. Exp Hematol 1996; 24:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onyike AE, Ohene-Frempong K, Horiuchi K. Sickling in vitro at venous and arterial oxygen tensions of reticulocytes from patients with sickle cell disease. Biochem Biophys Res Commun 1995; 211:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark MR, Mohandas N, Shohet SB. Deformability of oxygenated irreversibly sickled cells. J Clin Invest 1980; 65:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 1987; 237:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiuchi K, Ballas SK, Asakura T. The effect of deoxygenation rate on the formation of irreversibly sickled cells. Blood 1988; 71:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiuchi K, Asakura T. Oxygen promotes sickling of SS cells. Ann N Y Acad Sci 1989; 565:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011; 86:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant GR, Serjeant BE, Milner PF. The irreversibly sickled cell; a determinant of haemolysis in sickle cell anaemia. Br J Haematol 1969; 17:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest 2017; 127:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014; 123:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckman JD, Abdullah F, Chen C, et al. Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Front Immunol 2020; 11:613278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Z, Han H, Cruz MA, et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009; 101:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen G, Zhang D, Fuchs TA, et al. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood 2014; 123:3818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma R, Antypiuk A, Vance SZ, et al. Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease. Blood 2023; 141:3091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolosano E. Heme and macrophages: a complicated liaison. Blood 2023; 141:3015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamler JS, Jia L, Eu JP, et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997; 276:2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mondoro TH, Ryan BB, Hrinczenko BW, et al. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br J Haematol 2001; 112:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 2000; 63:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A 2001; 98:15215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci U S A 2005; 102:2531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JG 6th, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008; 3:e2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato GJ, Taylor JG 6th. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol 2010; 148:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon TJ, Shan S, Riccio DA, et al. Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo. Blood Adv 2019; 3:2586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol 2012; 87:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day ME, Rodeghier M, Driggers J, et al. A significant proportion of children of African descent with HbSβ0 thalassaemia are inaccurately diagnosed based on phenotypic analyses alone. Br J Haematol 2019; 185:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972; 287:846.
          </a>
         </li>
         <li class="breakAll">
          Song J. Pathology of Sickle Cell Disease, Thomas, Springfield 1971.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul DK, Fabry ME, Nagel RL. Erythrocytic and vascular factors influencing the microcirculatory behavior of blood in sickle cell anemia. Ann N Y Acad Sci 1989; 565:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A 1989; 86:3356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipowsky HH, Sheikh NU, Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest 1987; 80:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers GP, Schechter AN, Noguchi CT, et al. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med 1984; 311:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Embury SH, Mohandas N, Paszty C, et al. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest 1999; 103:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner MC, Eckman JR, Wick TM. Sickle cell adhesion depends on hemodynamics and endothelial activation. J Lab Clin Med 2004; 144:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol 1996; 3:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paik DT, Tian L, Williams IM, et al. Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells. Circulation 2020; 142:1848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunawardana H, Romero T, Yao N, et al. Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses. Sci Rep 2021; 11:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 1980; 302:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ansari J, Gavins FNE. Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. Am J Pathol 2019; 189:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbel RP, Belcher JD, Vercellotti GM. The multifaceted role of ischemia/reperfusion in sickle cell anemia. J Clin Invest 2020; 130:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers GM. Hemostatic properties of normal and perturbed vascular cells. FASEB J 1988; 2:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SC, Shacks SJ, Qu Z. In vivo production of type 1 cytokines in healthy sickle cell disease patients. J Natl Med Assoc 1999; 91:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourantas KL, Dalekos GN, Makis A, et al. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998; 61:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wun T. The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy. Hematology 2001; 5:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnog JJ, Lard LR, Rojer RA, et al. New concepts in assessing sickle cell disease severity. Am J Hematol 1998; 58:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setty BN, Betal SG. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood 2008; 111:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Z, Thiagarajan P, Udden M, et al. Erythrocyte membrane sulfatide plays a crucial role in the adhesion of sickle erythrocytes to endothelium. Thromb Haemost 2011; 105:1046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003; 101:3281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zennadi R, Hines PC, De Castro LM, et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 2004; 104:3774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zennadi R, Moeller BJ, Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2007; 110:2708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol 2005; 130:943.
          </a>
         </li>
         <li class="breakAll">
          Hebbel RP, Mohandas N. Sickle cell adherence. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.217.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111:5271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992; 80:2634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swerlick RA, Eckman JR, Kumar A, et al. Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993; 82:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setty BN, Stuart MJ, Dampier C, et al. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003; 362:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Closse C, Seigneur M, Renard M, et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res 1997; 85:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setty BN, Chen D, O'Neal P, et al. Eicosanoids in sickle cell disease: potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion. J Lab Clin Med 1998; 131:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood K, Russell J, Hebbel RP, Granger DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation 2004; 11:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui NM, Borsig L, Rosen SD, et al. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood 2001; 98:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002; 100:3790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 2004; 104:3378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hidalgo A, Chang J, Jang JE, et al. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 2009; 15:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbel RP, Visser MR, Goodman JL, et al. Potentiated adherence of sickle erythrocytes to endothelium infected by virus. J Clin Invest 1987; 80:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harlan JM. Introduction: anti-adhesion therapy in sickle cell disease. Blood 2000; 95:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997; 99:2561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med 2000; 342:1910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung U, Ley K. Mice lacking two or all three selectins demonstrate overlapping and distinct functions for each selectin. J Immunol 1999; 162:6755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lombardi E, Matte A, Risitano AM, et al. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica 2019; 104:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roumenina LT, Chadebech P, Bodivit G, et al. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 2020; 95:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chi JT, Chang HY, Haraldsen G, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003; 100:10623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul DK, Liu XD, Chang HY, et al. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest 2004; 114:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995; 96:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood 2008; 112:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werdehoff SG, Moore RB, Hoff CJ, et al. Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy. Am J Hematol 1998; 58:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graido-Gonzalez E, Doherty JC, Bergreen EW, et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998; 92:2551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammerman SI, Kourembanas S, Conca TJ, et al. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 1997; 156:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koehl B, Nivoit P, El Nemer W, et al. The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease. Haematologica 2017; 102:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003; 9:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zennadi R, Chien A, Xu K, et al. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 2008; 112:3474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veluswamy S, Shah P, Khaleel M, et al. Progressive vasoconstriction with sequential thermal stimulation indicates vascular dysautonomia in sickle cell disease. Blood 2020; 136:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalacheva P, Ji Y, Rosen CL, et al. Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease. Am J Hematol 2021; 96:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veluswamy S, Shah P, Denton CC, et al. Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation of the Microvasculature the Trigger? J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnan S, Setty Y, Betal SG, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol 2010; 148:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998; 351:959.
          </a>
         </li>
         <li class="breakAll">
          Chien S, Usami S, Skalak R. Blood flow in small tubes. In: Handbook of Physiology, Renkin EM, Michel CC, Geiger SR (Eds), American Physiological Society, Bethesda, MD 1993. p.217.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood 2004; 104:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol 2004; 76:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med 2001; 20:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnegan EM, Turhan A, Golan DE, Barabino GA. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. Am J Hematol 2007; 82:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A 2002; 99:3047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Y, Jing F, Yi W, et al. HO-1hi patrolling monocytes protect against vaso-occlusion in sickle cell disease. Blood 2018; 131:1600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vercellotti GM, Dalmasso AP, Schaid TR Jr, et al. Critical role of C5a in sickle cell disease. Am J Hematol 2019; 94:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe C, Jacob E, Styles L, et al. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol 2017; 177:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stankovic Stojanovic K, Thiolière B, Garandeau E, et al. Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis? Br J Haematol 2011; 155:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopinto J, Gendreau S, Berti E, et al. Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis. Haematologica 2022; 107:1914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter O, Cougoul P, Maquet J, et al. Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. Blood 2022; 139:3771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees DC, Kilinc Y, Unal S, et al. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood 2022; 139:2642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987; 27:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmalzer E, Chien S, Brown AK. Transfusion therapy in sickle cell disease. Am J Pediatr Hematol Oncol 1982; 4:395.
          </a>
         </li>
         <li class="breakAll">
          Vichinsky E. Transfusion. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.781.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah P, Khaleel M, Thuptimdang W, et al. Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls. Haematologica 2020; 105:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thuptimdang W, Shah P, Khaleel M, et al. Vasoconstriction Response to Mental Stress in Sickle Cell Disease: The Role of the Cardiac and Vascular Baroreflexes. Front Physiol 2021; 12:698209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin SR, Shah P, Denton C, et al. Autonomically-mediated decrease in microvascular blood flow due to mental stress and pain in sickle cell disease: A target for neuromodulatory interventions. Complement Ther Med 2020; 49:102334.
          </a>
         </li>
         <li class="breakAll">
          Francis RB Jr, Hebbel RP. Hemostasis. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.299.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordeuk VR. Sickle cell vaso-occlusion: the clot thickens. Blood 2020; 135:1726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparkenbaugh EM, Henderson MW, Miller-Awe M, et al. Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. Blood 2023; 141:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunson A, Lei A, Rosenberg AS, et al. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol 2017; 178:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011; 153:92.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7135 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29526279" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29526279" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29526279" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/284392" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35271708" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetic variants of PKLR are associated with acute pain in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9886305" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28423290" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30332562" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pathophysiology of Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33283989" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : CRISPR-Cas9 Gene Editing for Sickle Cell Disease andβ-Thalassemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33283990" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34898139" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/914634" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of 2, 3-diphosphoglycerate on the solubility of deoxy-sickle hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393711" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4673540" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The interaction of sickle hemoglobin with DPG, CO 2 and with other hemoglobins: formation of asymmetrical hybrids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/663663" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Aggregation effects on oxygen binding of sickle cell hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30335" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Oxygen affinity as an index of hemoglobin S polymerization: a new micromethod.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/469939" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Oxygen binding to sickle cell hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7120411" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Oxygen binding by sickle cell hemoglobin polymers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Thermodynamics of gelation of sickle cell deoxyhemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1177306" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Calorimetric and optical characterization of sickle cell hemoglobin gelation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4799" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Thermodynamic studies of polymerization of deoxygenated sickle cell hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2195851" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sickle cell hemoglobin polymerization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3311198" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hemoglobin S gelation and sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Sickle-cell hemoglobin
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31747289" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : On the Nonaggregation of Normal Adult Hemoglobin and the Aggregation of Sickle Cell Hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32940" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An increased Bohr effect in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6961429" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Molecular and cellular pathogenesis of hemoglobin SC disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7174796" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14022587" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16902" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Participation of hemoglobins A and F in polymerization of sickle hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6190521" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2895770" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Facilitation of Hb S polymerization by the substitution of Glu for Gln at beta 121.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1153003" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Role of hybrid tetramer formation in gelation of haemoglobin S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2359460" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nucleation and growth of fibres and gel formation in sickle cell haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26975885" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Calibrating Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/480359" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Three-dimensional reconstruction of the 14-filament fibers of hemoglobin S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4869055" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The fine structure of sickled hemoglobin in situ.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5795766" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Reversible and irreversible sickling: a distinction by electron microscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4123929" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Structure of fibers of sickle cell hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/692655" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Three-dimensional reconstruction of the fibres of sickle cell haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4594393" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ultrastructural features of erythrocyte and hemoglobin sickling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4710369" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The in vivo sickle phenomenon: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4710369" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The in vivo sickle phenomenon: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34040079" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Large red cell-derived membrane particles are major contributors to hypercoagulability in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32285120" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1650770" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Red cell volume-related ion transport systems in hemoglobinopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1650770" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Red cell volume-related ion transport systems in hemoglobinopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23519154" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Disorders of red cell volume regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23519154" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Disorders of red cell volume regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1201249" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Ultrastructural studies of the bone marrow in sickle cell anaemia. II. The morphology of erythropoietic cells and their response to deoxygenation in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8536795" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7794262" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sickling in vitro at venous and arterial oxygen tensions of reticulocytes from patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7350198" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Deformability of oxygenated irreversibly sickled cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3603036" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3334900" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The effect of deoxygenation rate on the formation of irreversibly sickled cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Oxygen promotes sickling of SS cells
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21264896" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5362290" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The irreversibly sickled cell; a determinant of haemolysis in sickle cell anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28248201" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Intravascular hemolysis and the pathophysiology of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020327" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pulmonary complications of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24277079" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33542720" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19492149" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24620350" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36952641" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37347498" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Heme and macrophages: a complicated liaison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197264" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11298605" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706764" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11132219" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12426562" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15811985" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16291595" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18422994" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11752464" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12626350" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699345" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Impaired vasodilation by red blood cells in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18461136" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19958359" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pleiotropic effects of intravascular haemolysis on vascular homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31484636" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22641398" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Genetic modifiers of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29797315" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A significant proportion of children of African descent with HbSβ0 thalassaemia are inaccurately diagnosed based on phenotypic analyses alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5071963" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Occlusion of large cerebral vessels in sickle-cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5071963" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Occlusion of large cerebral vessels in sickle-cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2672967" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Erythrocytic and vascular factors influencing the microcirculatory behavior of blood in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2497465" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3597770" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Intravital microscopy of capillary hemodynamics in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6504081" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Periodic microcirculatory flow in patients with sickle-cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10079113" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570244" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Sickle cell adhesion depends on hemodynamics and endothelial activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8675655" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9372061" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Molecular basis of sickle cell-endothelial cell interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32929989" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Single-Cell RNA Sequencing Unveils Unique Transcriptomic Signatures of Organ-Specific Endothelial Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33479269" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7366623" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30904156" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32118586" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The multifaceted role of ischemia/reperfusion in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2219269" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The role of endothelial cells in inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1690903" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Cytokines and endothelial cell biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3277885" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Hemostatic properties of normal and perturbed vascular cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3029867" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The regulation of natural anticoagulant pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10641497" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : In vivo production of type 1 cytokines in healthy sickle cell disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9688292" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Acute phase proteins and interleukins in steady state sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11399640" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9590151" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : New concepts in assessing sickle cell disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17911385" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21437360" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Erythrocyte membrane sulfatide plays a crucial role in the adhesion of sickle erythrocytes to endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506027" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15308566" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17609430" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16156864" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16156864" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502843" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The vessel wall and its interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1384794" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7691241" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602439" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058490" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9579388" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Eicosanoids in sickle cell disease: potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15280076" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11535535" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : P-selectin mediates the adhesion of sickle erythrocytes to the endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393591" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271798" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19305412" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3680511" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Potentiated adherence of sickle erythrocytes to endothelium infected by virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10627435" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Introduction: anti-adhesion therapy in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169483" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10861330" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10352295" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Mice lacking two or all three selectins demonstrate overlapping and distinct functions for each selectin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30630982" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31990387" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963823" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Endothelial cell diversity revealed by global expression profiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489961" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027074" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Endothelial cell responses to hypoxic stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635951" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18411415" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9662270" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746797" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230761" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Endothelin-1 production during the acute chest syndrome in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28385784" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12724752" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Nitric oxide's reactions with hemoglobin: a view through the SNO-storm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18664622" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32518948" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Progressive vasoconstriction with sequential thermal stimulation indicates vascular dysautonomia in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33027545" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31618931" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation of the Microvasculature the Trigger?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19995398" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7993409" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Mortality in sickle cell disease. Life expectancy and risk factors for early death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9414296" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Cerebrovascular accidents in sickle cell disease: rates and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9734950" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Granulocytosis causing sickle-cell crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9734950" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Granulocytosis causing sickle-cell crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15031206" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15164377" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Inflammatory potential of neutrophils detected in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12673844" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17094094" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11880644" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437594" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : HO-1hi patrolling monocytes protect against vaso-occlusion in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30569594" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Critical role of C5a in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17932253" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28369718" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21488859" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35021607" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35471555" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35226723" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3590284" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Transfusion therapy in sickle cell disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Transfusion therapy in sickle cell disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30975906" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34803725" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Vasoconstriction Response to Mental Stress in Sickle Cell Disease: The Role of the Cardiac and Vascular Baroreflexes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32147052" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Autonomically-mediated decrease in microvascular blood flow due to mental stress and pain in sickle cell disease: A target for neuromodulatory interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32147052" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Autonomically-mediated decrease in microvascular blood flow due to mental stress and pain in sickle cell disease: A target for neuromodulatory interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11385360" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Thrombogenesis in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17854302" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32407525" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Sickle cell vaso-occlusion: the clot thickens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36706361" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28369826" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21323872" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
